Last edition
News about "NSCLC treatment"
Xcovery Partners with EVERSANA to Launch Ensacove in US
Xcovery Holdings Inc. partners with EVERSANA to commercialize Ensacove in the U.S., leveraging end-to-end services including market access, medical and commercial support to expand lung cancer treatment availability.
NSCLC Treatment | 28/04/2026 | By News Bureau
MHRA Approves Bayer's Sevabertinib for HER2-Mutated Advanced Lung Cancer
Sevabertinib, a targeted therapy for HER2-mutated lung cancer, has been approved by the UK regulator to expand treatment options for advanced-stage patients.
NSCLC Treatment | 04/04/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy